Lumida
/ISRG
⌘K
Intuitive Surgical Inc

Intuitive Surgical Inc

ISRG
$369.15USD+2.41%+8.69 today

MARKET CAP

130.4B

P/E (TTM)

35.2x

FWD P/E

31.3x

DAY RANGE

$364 – $374

52W RANGE

$329
$604

AI Summary

Stalk
TrimMedium

ISRG is in a Stage 3 distribution phase, with price tracing lower highs and lower lows beneath declining EMAs and no mean-reversion triggers. The medium-term bias is bearish, reinforced by the active Lower Highs & Lower Lows pattern signaling supply dominance. Short-term price is currently above the 9/20 EMAs without clear exhaustion, so execution should be deferred until rallies into the EMA/50-SMA cluster provide structurally favorable entry. The long-term downtrend remains intact below the 200-day SMA.

  • 85% of Q2 revenue from instruments and services on 13K installed systems.
  • FDA clearance of new gastrointestinal robotic system expands addressable market.
  • da Vinci 5 platform rollout risks supply-chain execution and gross margin dilution.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$5.7B$6.2B$7.1B$8.4B$10.1B
YoY %+31.0%+9.0%+14.5%+17.2%+20.5%
P / Sales23.0x15.5x16.6x22.6x20.4x
EV / Sales23.1x15.5x16.5x22.6x20.3x
Gross Profit, Adj.$4.0B$4.2B$4.7B$5.6B$6.6B
YoY %+38.4%+6.0%+12.7%+19.1%+17.9%
Margin %69.3%67.4%66.4%67.5%66.0%
EV / Gross Profit33.3x23.0x24.9x33.6x30.8x
EBITDA, Adj.$2.2B$2.0B$2.2B$2.8B$3.6B
YoY %+60.3%-8.5%+12.8%+28.2%+27.2%
Margin %37.7%31.7%31.2%34.1%36.0%
EV / EBITDA61.2x49.0x52.9x66.4x56.5x
EBIT$1.8B$1.6B$1.8B$2.3B$2.9B
YoY %+73.5%-13.4%+12.0%+32.9%+25.4%
Margin %31.9%25.3%24.8%28.1%29.3%
EV / EBIT72.3x61.1x66.6x80.5x69.5x
Net Income$1.7B$1.3B$1.8B$2.3B$2.9B
YoY %+60.7%-22.4%+36.0%+29.2%+23.0%
Net Margin29.9%21.3%25.2%27.8%28.4%
EPS (GAAP)$4.66$3.65$5.03$6.42$7.87
YoY %+58.5%-21.7%+37.8%+27.6%+22.6%